PD AMPK Activator Companies

AMPK Activator Companies for Parkinson's Disease

This page catalogs biotechnology and pharmaceutical companies developing AMPK (AMP-activated protein kinase) activator therapies for Parkinson's disease (PD). AMPK is a central regulator of cellular energy homeostasis and represents a promising therapeutic target for neurodegenerative diseases.

<div class="infobox">
<div class="infobox-header">AMPK Activator Pipeline Overview</div>
<div class="infobox-content">
<table>
<tr><th>Total Companies</th><td>6</td></tr>
<tr><th>Phase 2</th><td>1</td></tr>
<tr><th>Phase 1</th><td>1</td></tr>
<tr><th>Preclinical</th><td>4</td></tr>
</table>
</div>
</div>

Overview

AMPK Activator Companies for Parkinson's Disease

This page catalogs biotechnology and pharmaceutical companies developing AMPK (AMP-activated protein kinase) activator therapies for Parkinson's disease (PD). AMPK is a central regulator of cellular energy homeostasis and represents a promising therapeutic target for neurodegenerative diseases.

<div class="infobox">
<div class="infobox-header">AMPK Activator Pipeline Overview</div>
<div class="infobox-content">
<table>
<tr><th>Total Companies</th><td>6</td></tr>
<tr><th>Phase 2</th><td>1</td></tr>
<tr><th>Phase 1</th><td>1</td></tr>
<tr><th>Preclinical</th><td>4</td></tr>
</table>
</div>
</div>

Overview

AMPK activation represents a promising therapeutic approach for Parkinson's disease because:

• Energy metabolism: AMPK regulates mitochondrial biogenesis and function, addressing the bioenergetic defect in dopaminergic neurons
• Autophagy induction: AMPK activates autophagy, potentially clearing pathological alpha-synuclein aggregates
• Neuroinflammation: AMPK has anti-inflammatory effects in microglia
• Synaptic protection: Energy support protects synaptic function and dopaminergic neuron viability

Clinical-Stage Companies

Novo Nordisk A/S

Ticker: NASDAQ: NVO Headquarters: Copenhagen, Denmark

Novo Nordisk is evaluating Metformin, a known AMPK activator, in Parkinson's disease clinical trials. Metformin activates AMPK through mitochondrial complex I inhibition and has established safety data from decades of diabetes use.

| Drug | Mechanism | Phase | Trial ID |
|------|-----------|-------|----------|
| Metformin | AMPK activator (Complex I inhibition) | Phase 2 | NCT04032361 |
| Metformin | AMPK activator (cognitive effects) | Phase 2 | NCT03790617 |

Metformin represents a repurposing opportunity with a well-established safety profile. The company leverages its metabolic disease expertise to explore neurodegenerative applications. [@metforminpd]

Related pages:

• [Novo Nordisk](/companies/novo-nordisk)
• [PD Metabolic Intersection Companies](/companies/pd-metabolic-intersection-companies)
• [AMPK Activators in PD](/mechanisms/ampk-activators-parkinsons)

Eli Lilly and Company

Ticker: NYSE: LLY Headquarters: Indianapolis, Indiana, USA

Eli Lilly has explored Metformin in Parkinson's disease trials and maintains a broad program in metabolic-neurodegeneration intersection. Their metabolic disease portfolio positions them well for AMPK-related approaches.

| Drug | Mechanism | Phase | Status |
|------|-----------|-------|--------|
| Metformin | AMPK activator | Phase 2 | Completed |

Related pages:

• [Eli Lilly](/companies/eli-lilly)
• [Alzheimer's Disease GLP-1 Companies](/companies/ad-glp-1-metabolic-therapy-companies)

Preclinical-Stage Companies

###Research Compounds with AMPK Activity

The following companies and research groups have developed novel AMPK activator compounds in preclinical stages:

| Company | Compound | Mechanism | Development Stage |
|---------|----------|-----------|-------------------|
| Various (Academic) | AICAR | Direct AMPK activator (ZMP analog) | Research |
| Various (Academic) | PT1 | Allosteric AMPK activator | Research |
| Various (Academic) | A-769662 | Direct β1 subunit activator | Research |
| Various (Academic) | Thienopyridone derivatives | Brain-penetrant AMPK activators | Preclinical |

Note: AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) is a ZMP analog that directly activates AMPK. However, brain penetration has been limited. Current research focuses on:

• Prodrug approaches: AICAR prodrugs with improved brain penetration [@aicar]
• Allosteric activators: Compounds targeting specific AMPK conformations
• Isoform-selectivity: Beta1-selective activators for neuronal applications
• Combination strategies: AMPK activators combined with other mechanisms (e.g., LRRK2 inhibitors, GLP-1 agonists)

• [AMPK Signaling in PD](/mechanisms/ampk-signaling-parkinsons)
• [AMPK Mechanisms](/mechanisms/ampk-activators-parkinsons)

Emerging Approaches

Companies with AMPK-Adjacent Programs

Several companies have programs that activate AMPK through indirect mechanisms:

| Company | Drug/Approach | Indirect AMPK Activation | Status |
|---------|--------------|-------------------------|--------|
| Novo Nordisk | Semaglutide | GLP-1R agonism → AMPK activation | Phase 2 |
| Neuraly | NLY01 | GLP-1R agonism → AMPK activation | Phase 2 |
| Clene Nanomedicine | CNM-Au8 | Mitochondrial support → secondary AMPK effect | Phase 2 |

These companies target pathways that result in secondary AMPK activation, contributing to neuroprotection.

Related pages:

• [PD Metabolic Intersection Companies](/companies/pd-metabolic-intersection-companies)
• [GLP-1 Receptor Agonists](/therapeutics/glp-1-receptor-agonists)

Clinical Trial Landscape

Active AMPK-Targeting Trials in PD

| Trial ID | Drug | Company | Phase | Status |
|----------|------|---------|-------|--------|
| NCT04032361 | Metformin | Novo Nordisk | Phase 2 | Completed |
| NCT03790617 | Metformin | Various | Phase 2 | Completed |

Key Challenges

Scientific Rationale

AMPK Biology in PD

AMPK (AMP-activated protein kinase) is a central cellular energy sensor that:

• Activates when cellular AMP/ATP ratio increases
• Regulates mitochondrial biogenesis via PGC-1α
• Induces autophagy through mTOR inhibition
• Modulates inflammation in microglia
• Protects against oxidative stress

Preclinical Evidence

• AICAR improves motor performance in 6-OHDA and MPTP models
• Metformin reduces neurodegeneration in animal models
• AMPK activation reduces alpha-synuclein aggregation
• Combination approaches show enhanced efficacy

Cross-References

• [AMPK Activators in Parkinson's Disease](/mechanisms/ampk-activators-parkinsons)
• [AMPK Signaling Pathway](/mechanisms/ampk-signaling-pathway)
• [PD Metabolic Intersection Companies](/companies/pd-metabolic-intersection-companies)
• [Parkinson's Disease Treatments](/therapeutics/parkinsons-disease-treatments)
• [Parkinson's Disease Pipeline](/companies/pd-pipeline)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving PD AMPK Activator Companies discovered through SciDEX knowledge graph analysis: